as mentioned in The White House announced Friday that President Donald Trump intends to nominate Scott Gottlieb as the new commissioner of the Food and Drug Administration Gottlieb, a physician, previously served as deputy commissioner for medical and scientific affairs with the FDA during the administration of President George W. Bush.
The agency was most recently overseen by Commissioner Robert Califf, who held the role from February 2016 until Trump’s inauguration.
He is currently a partner at New Enterprise Associates specializing in health care investments and is a resident fellow at the American Enterprise Institute.Gottlieb will require Senate confirmation before he can assume the position leading the group, which oversees the safety of food and pharmaceuticals in the U.S.The FDA lies within the Department of Health and Human Services, which is led by another doctor, Tom Price.
as informed in
White House official: President Trump to name former FDA official Scott Gottlieb as agency commissioner
http://www.seattlepi.com/news/medical/article/White-House-official-President-Trump-to-name-10993342.phpWhite House official: President Trump to name former FDA official Scott Gottlieb as agency commissioner
as informed in Scott Gottlieb, President-elect Donald Trump’s presumptive nominee for FDA commissioner, has strong conservative credentials and a close relationship with the pharmaceutical industry.
If the Senate approves Gottlieb as FDA commissioner, big-ticket items before him will include hastening those approvals, as well as shaping the future of clinical trial requirements.
Other early tests will come from how the Trump administration and the Republican-led Congress act on drug pricing issues.
Gottlieb already has significant ties to the FDA and other federal agencies.
He is currently a resident fellow at the conservative American Enterprise Institute, where he analyzes health policy, regulation and public health.
This content may collect you by Luaren Colin